WallStreetZenWallStreetZen

NASDAQ: OPK
Opko Health Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for OPK

Based on 2 analysts offering 12 month price targets for Opko Health Inc

Min Forecast
$1.60+19.4%
Avg Forecast
$1.93+43.66%
Max Forecast
$2.25+67.91%

Should I buy or sell OPK stock?

Based on 2 analysts offering ratings for Opko Health Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OPK's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates OPK as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their OPK stock forecasts and price targets.

OPK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-31
lockedlocked$00.00+00.00%2025-10-30

1 of 1

Forecast return on equity

Is OPK forecast to generate an efficient return?

Company
N/A
Industry
11.69%
Market
228.52%

Forecast return on assets

Is OPK forecast to generate an efficient return on assets?

Company
N/A
Industry
14.28%

OPK earnings per share forecast

What is OPK's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.33
Avg 2 year Forecast
-$0.26
Avg 3 year Forecast
-$0.14

OPK revenue forecast

What is OPK's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$604.1M-5.91%
Avg 2 year Forecast
$586.8M-8.61%
Avg 3 year Forecast
$638.2M-0.61%
OPK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OPK revenue growth forecast

How is OPK forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
-1.24%
Industry
5.44%
Market
25.67%
OPK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OPK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OPK vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
OPK$1.34$1.93+43.66%Buy
CDNA$18.53$21.67+16.93%Buy
CSTL$38.64$38.67+0.07%Strong Buy
FLGT$27.79$30.00+7.95%Buy
PSNL$9.56$11.60+21.34%Buy
View Top Diagnostic & Research Stocks

Opko Health Stock Forecast FAQ

Is Opko Health Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: OPK) stock is to Buy OPK stock.

Out of 2 analysts, 0 (0%) are recommending OPK as a Strong Buy, 1 (50%) are recommending OPK as a Buy, 1 (50%) are recommending OPK as a Hold, 0 (0%) are recommending OPK as a Sell, and 0 (0%) are recommending OPK as a Strong Sell.

If you're new to stock investing, here's how to buy Opko Health stock.

What is OPK's earnings growth forecast for 2025-2027?

(NASDAQ: OPK) Opko Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 16.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Opko Health's earnings in 2025 is -$180,396,000.On average, 8 Wall Street analysts forecast OPK's earnings for 2025 to be -$253,648,503, with the lowest OPK earnings forecast at -$263,321,539, and the highest OPK earnings forecast at -$241,825,903. On average, 8 Wall Street analysts forecast OPK's earnings for 2026 to be -$200,523,574, with the lowest OPK earnings forecast at -$308,462,374, and the highest OPK earnings forecast at -$104,791,225.

In 2027, OPK is forecast to generate -$108,552,961 in earnings, with the lowest earnings forecast at -$188,086,814 and the highest earnings forecast at -$56,426,044.

What is OPK's revenue growth forecast for 2025-2027?

(NASDAQ: OPK) Opko Health's forecast annual revenue growth rate of -1.24% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Opko Health's revenue in 2025 is $642,066,000.On average, 8 Wall Street analysts forecast OPK's revenue for 2025 to be $463,760,666,235, with the lowest OPK revenue forecast at $447,646,616,368, and the highest OPK revenue forecast at $488,327,107,195. On average, 8 Wall Street analysts forecast OPK's revenue for 2026 to be $450,471,757,078, with the lowest OPK revenue forecast at $402,505,781,104, and the highest OPK revenue forecast at $522,343,950,912.

In 2027, OPK is forecast to generate $489,908,571,832 in revenue, with the lowest revenue forecast at $459,684,172,438 and the highest revenue forecast at $537,659,591,448.

What is OPK's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: OPK) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 14.28%.

What is OPK's Price Target?

According to 2 Wall Street analysts that have issued a 1 year OPK price target, the average OPK price target is $1.93, with the highest OPK stock price forecast at $2.25 and the lowest OPK stock price forecast at $1.60.

On average, Wall Street analysts predict that Opko Health's share price could reach $1.93 by Oct 31, 2026. The average Opko Health stock price prediction forecasts a potential upside of 43.66% from the current OPK share price of $1.34.

What is OPK's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: OPK) Opko Health's current Earnings Per Share (EPS) is -$0.24. On average, analysts forecast that OPK's EPS will be -$0.33 for 2025, with the lowest EPS forecast at -$0.34, and the highest EPS forecast at -$0.32. On average, analysts forecast that OPK's EPS will be -$0.26 for 2026, with the lowest EPS forecast at -$0.40, and the highest EPS forecast at -$0.14. In 2027, OPK's EPS is forecast to hit -$0.14 (min: -$0.25, max: -$0.07).

What is OPK's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: OPK) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.